Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated
Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF
Expanded Intellectual Property Estate for Levosimendan with Issuance of New U.S. Patent
Recently Hosted KOL Event, “LEVEL Setting,” Featuring Four Experts in Heart Failure Discussing the Unmet Medical Need in PH-HFpEF and Potential of Levosimendan to Address Disease
Raised Approximately $8 Million of Net Proceeds in Registered Public Offering in February 2024
CHAPEL HILL, N.C., May 14, 2024 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced financial results for the first quarter of 2024 and provided a corporate update.
“The first quarter of 2024 was a productive and historically important period for Tenax Therapeutics, highlighted by the initiation of our Phase 3 LEVEL study evaluating TNX-1o3 (oral levosimendan) for the treatment of PH-HFpEF,” said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics. “We were also able to expand our patent estate and secure global commercial rights for levosimendan for the treatment of PH-HFpEF. In April, we hosted a KOL event entitled “LEVEL Setting,” featuring four prominent experts in the field of heart failure discussing the pathophysiology of PH-HFpEF and the potential for levosimendan to address one of the largest unmet needs in cardiovascular medicine.”
“As we approach the midpoint of 2024, we continue initiating trial sites and enrolling patients in LEVEL. We are excited to see the cardiology community enthusiastically embracing this Phase 3 study. We plan to provide updates on the TNX-103 program later this year.”
Recent Corporate and Clinical Highlights
First Quarter 2024 Financial Results
Tenax Therapeutics reported cash and cash equivalents of $12.5 million as of March 31, 2024. In February 2024, the Company raised approximately $8.0 million of net proceeds in a registered public offering.
Research and Development expenses for the first quarter of 2024 were $2.7 million, compared to $265 thousand for the first quarter of 2023. The $2.4 million increase year-over-year is primarily attributable to increased costs for the ongoing Phase 3 LEVEL study.
General and administrative expenses for the first quarter of 2024 were $1.2 million which were comparable to the first quarter of 2023.
Tenax Therapeutics reported a net loss for the first quarter of 2024 of $3.8 million, compared to a net loss of $1.4 million the first quarter of 2023.
About the Phase 3 LEVEL Study (NCT05983250)
The LEVEL Study is a Phase 3, double-blind, randomized, placebo-controlled study of levosimendan in patients with PH-HFpEF. Approximately 152 subjects will be randomized in a 1:1 ratio to receive an oral dose of levosimendan (2 mg/day) or placebo for Weeks 1 to 4 and 3 mg/day or placebo for Weeks 5 to 12. The primary outcome measure for the study is change in six-minute walk distance from Baseline to Week 12. All randomized subjects will have the option to enter the 92-week OLE following the completion of all study events at Week 12.
About Levosimendan (TNX-101, TNX-102, TNX-103)
Levosimendan is a unique, potassium ATP channel activator and calcium sensitizer that affects the heart and vascular system through multiple mechanisms of action. Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan has been granted marketing authorization in over 60 countries outside the United States for use in hospitalized patients with acutely decompensated heart failure. Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. levosimendan produces potent dilation of the central and pulmonary venous circulations which translates into an improvement in exercise capacity, a discovery that is the basis of LEVEL, the Phase 3 investigation of Tenax Therapeutics’ potential groundbreaking therapy. To date, no other drug therapy has improved exercise tolerance in patients with PH associated with HFpEF, “a growing epidemic with high morbidity and mortality and no treatment. The clear unmet need and lethal nature of PH-HFpEF must be met with novel solutions at all levels of therapeutic development” (AHA Scientific Advisory, “A Call to Action,” 2022).
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company owns global rights to develop and commercialize levosimendan, which it has prioritized in the near term. Tenax Therapeutics also may resume developing its unique oral formulation of imatinib. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
Caution Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. These forward-looking statements may include information concerning possible or projected future business operations. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; risks related to our business strategy, including the prioritization and development of product candidates; risks of our clinical trials, including, but not limited to, the timing, delays, costs, design, initiation, enrollment, and results of such trials; any delays in regulatory review and approval of product candidates in development; reliance on third parties, including Orion Corporation, our manufacturers and CROs; risks regarding the formulation, production, marketing, customer acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; the potential advantages of our product candidates; our competitive position; intellectual property risks; risks related to our continued listing on Nasdaq; our ability to maintain our culture and recruit, integrate and retain qualified personnel and advisors, including on our Board of Directors; volatility and uncertainty in the global economy and financial markets in light of the possibility of pandemics, global financial and geopolitical uncertainties, including in the Middle East and the Russian invasion of and war against the country of Ukraine; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and other risks and uncertainties set forth from time to time in our SEC filings. Tenax Therapeutics assumes no obligation and does not intend to update these forward-looking statements except as required by law.
Contacts
Investor Contact:
John Fraunces
Managing Director
LifeSci Advisors, LLC
C: 917-355-2395, or
Brian Mullen
LifeSci Advisors, LLC
C: 203-461-1175
Tenax Therapeutics, Inc. – Consolidated Balance Sheet | |||||||
for the Periods Ended March 31, 2024 and December 31, 2023 | |||||||
March 31, 2024 | December 31, 2023 | ||||||
(Unaudited) | |||||||
ASSETS | |||||||
Current assets | |||||||
Cash and cash equivalents | $ | 12,549,475 | $ | 9,792,130 | |||
Prepaid expenses | 1,843,047 | 1,639,797 | |||||
Other current assets | 66,625 | 251,583 | |||||
Total current assets | 14,459,147 | 11,683,510 | |||||
Other assets | 1,117 | 1,117 | |||||
Total assets | $ | 14,460,264 | $ | 11,684,627 | |||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
Current liabilities | |||||||
Accounts payable | $ | 1,080,962 | $ | 2,073,149 | |||
Accrued liabilities | 536,443 | 1,012,468 | |||||
Note Payable | 413,174 | 500,903 | |||||
Total current liabilities | 2,030,579 | 3,586,520 | |||||
Total liabilities | 2,030,579 | 3,586,520 | |||||
Commitments and contingencies; | |||||||
Stockholders’ equity | |||||||
Preferred stock, undesignated, authorized 4,818,654 shares; | |||||||
Series A Preferred stock, par value $.0001, authorized 5,181,346 shares; issued and outstanding 210, as of March 31, 2024 and December 31, 2023, respectively | – | – | |||||
Common stock, par value $.0001 per share; authorized 400,000,000 shares; issued and outstanding 1,958,245 as of March 31, 2024 and 298,281 as of December 31, 2023, respectively | 196 | 30 | |||||
Additional paid-in capital | 313,481,082 | 305,350,830 | |||||
Accumulated deficit | (301,051,593 | ) | (297,252,753 | ) | |||
Total stockholders’ equity | 12,429,685 | 8,098,107 | |||||
Total liabilities and stockholders’ equity | $ | 14,460,264 | $ | 11,684,627 |
Tenax Therapeutics, Inc. – Consolidated Income Statement | ||||||||
for the Periods Ended March 31, 2024 and March 31, 2023 | ||||||||
Three months ended March 31, | ||||||||
2024 | 2023 | |||||||
Operating expenses | ||||||||
General and administrative | $ | 1,232,674 | $ | 1,273,730 | ||||
Research and development | 2,675,652 | 265,735 | ||||||
Total operating expenses | 3,908,326 | 1,539,465 | ||||||
Net operating loss | 3,908,326 | 1,539,465 | ||||||
Interest expense | 7,963 | 7,350 | ||||||
Interest income | – | |||||||
Other expense (income), net | (117,449 | ) | (140,055 | ) | ||||
Net loss | $ | (3,798,840 | ) | $ | (1,406,760 | ) | ||
Net loss per share, basic and diluted | $ | (3.12 | ) | $ | (12.10 | ) | ||
Weighted average number of common shares outstanding, basic and diluted | 1,219,139 | 116,259 |
BEIJING--(BUSINESS WIRE)--Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered…
Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF…
SOUTH SAN FRANCISCO, Calif., June 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO),…
Vancouver, BC, June 07, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology…
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX,…
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2024) - Numinus Wellness Inc. (TSX: NUMI) (OTCQX:…